BXN Stock Overview
A life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bioxyne Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.02 |
| 52 Week High | AU$0.053 |
| 52 Week Low | AU$0.004 |
| Beta | 0.34 |
| 1 Month Change | -23.08% |
| 3 Month Change | -57.45% |
| 1 Year Change | 185.71% |
| 3 Year Change | 33.33% |
| 5 Year Change | 42.86% |
| Change since IPO | -89.47% |
Recent News & Updates
Bioxyne Limited's (ASX:BXN) Share Price Is Still Matching Investor Opinion Despite 26% Slump
Apr 28
Bioxyne Limited (ASX:BXN) Shares Slammed 46% But Getting In Cheap Might Be Difficult Regardless
Mar 11Shareholder Returns
| BXN | AU Personal Products | AU Market | |
|---|---|---|---|
| 7D | -13.0% | -0.4% | 3.5% |
| 1Y | 185.7% | 15.0% | 5.9% |
Return vs Industry: BXN exceeded the Australian Personal Products industry which returned 15% over the past year.
Return vs Market: BXN exceeded the Australian Market which returned 5.9% over the past year.
Price Volatility
| BXN volatility | |
|---|---|
| BXN Average Weekly Movement | 21.5% |
| Personal Products Industry Average Movement | 6.3% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 16.6% |
| 10% least volatile stocks in AU Market | 4.1% |
Stable Share Price: BXN's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: BXN's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Sam Watson | bioxyne.com |
Bioxyne Limited, a life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, cannabis pastilles, THC flowers, vapes, oral liquids, nootropic and skin care products, and mushroom complexes. It also develops various functional food products, such as lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products.
Bioxyne Limited Fundamentals Summary
| BXN fundamental statistics | |
|---|---|
| Market cap | AU$43.30m |
| Earnings (TTM) | AU$2.59m |
| Revenue (TTM) | AU$17.33m |
16.7x
P/E Ratio2.5x
P/S RatioIs BXN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXN income statement (TTM) | |
|---|---|
| Revenue | AU$17.33m |
| Cost of Revenue | AU$9.24m |
| Gross Profit | AU$8.09m |
| Other Expenses | AU$5.50m |
| Earnings | AU$2.59m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0012 |
| Gross Margin | 46.66% |
| Net Profit Margin | 14.93% |
| Debt/Equity Ratio | 5.3% |
How did BXN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 10:03 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bioxyne Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.